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Background: The purpose of this study was to examine the short-term and chronic effects of β-ALA supplementation
with and without creatine monohydrate on body composition, aerobic and anaerobic exercise performance, and
muscle carnosine and creatine levels in college-aged recreationally active females.
Methods: Thirty-two females were randomized in a double-blind, placebo-controlled manner into one of four
supplementation groups: β-ALA only (BA, n = 8), creatine only (CRE, n = 8), β-ALA and creatine combined (BAC,
n = 9) and placebo (PLA, n = 7). Participants supplemented for four weeks included a loading phase for the creatine
for week 1 of 0.3 g/kg of body weight and a maintenance phase for weeks 2–4 of 0.1 g/kg of body weight, with or
without a continuous dose of β-ALA of 0.1 g/kg of body weight with doses rounded to the nearest 800 mg capsule
providing an average of 6.1 ± 0.7 g/day of β-ALA. Participants reported for testing at baseline, day 7 and day 28.
Testing sessions consisted of obtaining a resting muscle biopsy of the vastus lateralis, body composition measurements,
performing a graded exercise test on the cycle ergometer for VO2peak with lactate threshold determination, and
multiple Wingate anaerobic capacity tests.
Results: Although mean changes were consistent with prior studies and large effect sizes were noted, no
significant differences were observed among groups in changes in muscle carnosine levels (BA 35.3 ± 45; BAC
42.5 ± 99; CRE 0.72 ± 27; PLA 13.9 ± 44%, p = 0.59). Similarly, although changes in muscle phosphagen levels after one
week of supplementation were consistent with prior reports and large effect sizes were seen, no statistically significant
effects were observed among groups in changes in muscle phosphagen levels and the impact of CRE supplementation
appeared to diminish during the maintenance phase. Additionally, significant time × group × Wingate interactions
were observed among groups for repeated sprint peak power normalized to bodyweight (p = 0.02) and rate of
fatigue (p = 0.04).
Conclusions: Results of the present study did not reveal any consistent additive benefits of BA and CRE
supplementation in recreationally active women.* Correspondence: rkreider@hlkn.tamu.edu
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Prior research has shown that beta-alanine (β-ALA)
supplementation (e.g., 3.2 g/day to 6.4 g/day for 2 to
10-weeks) increases in muscle carnosine levels, with
greater increases observed when larger total dosages
have been consumed over time [1-8]. It has been suggested
that an increase in intramuscular carnosine levels may
lead to an enhanced muscle buffering capacity therefore
improving performance by limiting the accumulation of
hydrogen ions (H+) [2,4,6,7,9,10]. The amount of carno-
sine elevation ranges from around 10% after two weeks [8]
to around 80% after ten weeks [10]. A recent review on
the ergogenic benefits of β-ALA supplementation sug-
gested bouts of exercise lasting 1–3 minutes seemed to
provide the most benefit with mixed results seen during
shorter bouts of exercise [11]. There is also some evidence
suggesting that β-ALA supplementation may positively
affect body composition when combined with training
[12], time to exhaustion [5,11], anaerobic exercise markers
such as ventilatory threshold (VT) [13], as well as blood
lactate levels [14,15]. The effects of creatine monohydrate
have been extensively researched over recent years with
respects to the effects on anaerobic exercise performance
[16]. High intensity exercise bouts require a faster rate
of ATP resynthesis, which is most quickly attained by
breaking down phosphocreatine (PCr) [17,18]. Creatine
monohydrate supplementation (e.g., 20 g/day for 5 to
7-days and 3–5 g/day thereafter) has been shown to
increase the muscle creatine and PCr stores to assist in
ATP resynthesis during high intensity exercise [19-21].
Given the reported ergogenic value of β-ALA and creat-
ine supplementation, recent studies have begun to examine
the combined effects of β-ALA and creatine monohydrate
supplementation on anaerobic exercise performance and
muscle carnosine and creatine levels. Results have shown
improvements in exercise performance variables such as
peak oxygen uptake (VO2peak), lactate threshold (LT), and
time to exhaustion with a combined supplementation
strategy [15]. Similarly, Hoffman and colleagues [22]
reported that 10-weeks of β-ALA and creatine monohy-
drate supplementation during resistance-training had
both independent and potentially synergistic ergogenic
benefits in male strength/power athletes. However, more
research is needed to determine whether there may be
additive benefit of co-supplementation of β-ALA and
creatine monohydrate supplementation during training.
Additionally, the majority of beta-alanine and creatine
supplementation studies have used males as participants.
Therefore, while it is generally understood how beta-
alanine supplementation can affect muscle carnosine
levels as well as exercise performance in men, less is
known how females will respond to beta-alanine supple-
mentation during training [9,13,14,22-24]. Studies that
have examined the effects of β-ALA supplementation inwomen have reported mixed results [25,26]. Therefore,
the purpose of this study was to examine the short-term
(7-days) and chronic effects (28-days) of β-ALA supple-
mentation with and without creatine monohydrate on
body composition, aerobic and anaerobic exercise per-
formance, and muscle carnosine and muscle creatine
levels in college-aged, recreationally-active females. We
theorized that co-supplementation of β-ALA and creatine
monohydrate may lead to greater ergogenic and perform-
ance adaptations by synergistically enhancing anaerobic
and/or aerobic capacity.
Methods
Experimental design
The present study was a randomized double-blind,
placebo-controlled trial that recruited apparently healthy,
moderately active females between the ages of 18 and
35 years to participate in the study. Moderately active
was defined as having a consistent recent history of
participating in exercise (e.g., running, cycling, swimming,
resistance training, fitness classes, etc.) for at least
30 minutes per day for 3-days per-week for at least
3 months. Participants were not allowed to participate
if they had taken ergogenic levels of nutritional supple-
ments that may have affected muscle mass or anaerobic
exercise capacity (i.e. creatine, β-ALA, ergogenic levels
of nutritional caffeine, etc.) for at least three months
prior to the start of the study. Those who met entrance
criteria attended a familiarization session during which
time they were familiarized to the study protocol with
verbal and written explanations of the study requirements.
Participants still interested and meeting the entrance
criteria signed informed consent statements in compliance
with the Human Participants Guidelines of Texas A&M
University and the American College of Sports Medicine.
During the familiarization session, participants were also
weighed using a standing scale and asked to perform a
practice Wingate exercise test on the cycle ergometer at
75% maximal effort. Participants were instructed to find a
comfortable seat height and handle bar position which
was recorded for subsequent testing sessions. Following
the practice Wingate test they were given guidelines to
follow for maintaining and recording physical activity dur-
ing their involvement in the study and scheduled for all
subsequent testing sessions and randomly assigned to one
of four supplementation groups. Figure 1 shows a consort
diagram of those found eligible, initiated, and completed
the study protocol. Individuals who did not complete the
study did so for reasons unrelated to the study protocol.
Resting and exercise testing
Resting and exercise testing was performed at baseline
prior to any supplementation, at one week of supple-
mentation, and after four weeks at the completion of the
Figure 1 Consort diagram of study enrollment.
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Participants were asked to abstain from exercise for
24 hours and fast for at least eight hours prior to baseline
testing. One day prior to exercise testing, participants
received a percutaneous muscle biopsy from the vastus
lateralis muscle of the right leg using standard proceduresFigure 2 Outline of testing sessions.for the Bergstrom method [27]. Muscle samples were
immediately frozen at −80° until analyzed.
The morning after the biopsy, participants were asked
to fast for at least eight hours before being asked to
consume a standard meal replacement drink (Boost®
Original, Nestlé S.A.,Vevey, Switzerland) four hours before
reporting to the lab in order to standardize nutritional
intake prior to exercise testing. Once reporting to the lab,
they were weighed using a free standing scale (Cardinal
Detecto Scale Model 8430, Webb City, Missouri) and
had body composition determined using a Dual Energy
X-Ray Absorptiometer (DEXA) [Discovery QDR Series,
Hologic Inc., Waltham, MA]. Quality control calibration
procedures were performed on a spine phantom (Holo-
gic-X-CLAIBER Model DPA/QDR-1 anthropometric spine
phantom) and a density step calibration phantom prior
to each testing session. Mean test-retest reliability studies
performed on athletes in the lab had yielded mean coeffi-
cients of variation for total bone mineral content and total
fat free/soft tissue mass of 0.31% to 0.45% with a mean
intra-class correlation of 0.985 [28]. They then had their
total body water (TBW) measured using bioelectrical
impedance analysis (ImpediMed DF50, San Diego, CA).
Following the resting measures, participants began exer-
cise testing starting with a maximal graded exercise test
(GXT) using an incremental protocol on the Lode Excali-
ber Sport 925900 cycle ergometer (Lode BV, Groningen,
The Netherlands) with metabolic measurements recorded
on the ParvoMedics True One 2400 Metabolic System
(ParvoMedics, Sandy, Utah). The protocol began at 50 W
maintaining 70 rpm and the intensity was increased by
25 W every three minutes until a pedaling rate of 70 rpm
was no longer maintained. Previous research has indicated
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intra-class coefficient of variation of 4.7% when using
the ParvoMedics True One 2400 Metabolic system [29].
Calibration procedures were completed prior to each
testing session.
Blood samples were taken from the fingertips in the
final minute of each stage of exercise and five minutes
into the recovery to determine LT. Lactate was determined
using a Lactate Scout (Sports Resource Group, USA)
handheld analysis device. Previous research has yielded
a mean intra-class correlation of 0.91 and a mean intra-
class coefficient of variation of 10.2% [30]. Calibration
procedures were completed prior to each testing session.
The LT was calculated two different ways including the
point at which blood lactate concentrations rises more
than 1.0 mM/l from the previously recorded value LT and
the point at which blood lactate level was greater than or
equal to 4.0 (also termed the onset of blood lactate,
OBLA). All values were reported as a percent of VO2peak.
The ventilatory threshold (VT) was determined as the
point during the GXT where pulmonary ventilation
increased at a disproportional rate with VO2, and was
also recorded as a percent of VO2peak. Following the
GXT, participants rested passively for 30 minutes and
then performed two 30-sec Wingate Anaerobic Capacity
Tests at a standardized work rate of 7.5 J/kg/rev. The
seat position was standardized between trials and the
participant was asked to pedal as fast as possible prior to
application of the workload and sprint at all-out maximal
capacity during the 30-second test with 3 minutes of
passive rest in between. Blood was taken from the finger-
tips before the start of Wingate 1, immediately following
Wingate 2, and after 5 minutes of passive recovery follow-
ing the completion of both Wingate tests. Test-to-test
variability in performing repeated Wingate anaerobic
capacity tests in our laboratory yielded a coefficient of
variation (CV) of ±15% with a test retest correlation of
r = 0.98 for mean power [31]. Participants practiced the
anaerobic capacity test during the familiarization session
to minimize learning effects.
Supplementation protocol
The supplementation protocol was modified from those
used by Hoffman et al. in 2006 [22] and Zoeller et al. in
2007 [15]. The creatine monohydrate (Creapure®, AlzChem
Trostberg GmbH, Germany) supplementation was provided
in the form of a powder that the participants were
instructed to mix with water (6–10 oz.). The β-ALA
used in this study (CarnoSyn®, Natural Alternatives
International, Inc., San Marcos, CA) was a sustained
release form of β-ALA that was provide in 800 mg
capsules. In a double blinded manner, participants were
matched to body mass and randomly assigned to either
ingest β-ALA (BA, n = 8), creatine monohydrate (CRE,n = 8), a combination of β-ALA and creatine monohydrate
(BAC, n = 9), or a placebo (PLA, n = 7). The β-ALA only
group received a dose of 0.1 g/kg body weight per day for
the entire 28 days with 0.3 g/kg/day of dextrose for week
1 and 0.1 g/kg/day of dextrose for weeks 2–4. The creatine
only group was given a dose of 0.3 g/kg/day of creatine for
week 1 and 0.1 g/kg/day for weeks 2–4, with 0.1 g/kg/day
maltodextrin for the 28 days. The β-ALA and creatine
combined group consumed a 0.1 g/kg/day of β-ALA for
the entire 28 days (about 6.1 ± 0.7 g/day) with 0.3 g/kg/
day of creatine for week 1 (about 18 ± 1.8 g/day) and
0.1 g/kg/day of creatine for weeks 2–4 (about 6.1 ± 0.7 g/
day). Finally, the placebo group was given 0.1 g/kg/day of
maltodextrin capsules for all 28 days with 0.3 g/kg/day of
dextrose powder for week 1 and 0.1 g/kg/day for weeks
2–4 which served as the placebo for creatine monohy-
drate. The β-ALA and matched placebo doses were
rounded to the nearest 800 mg capsule while the creatine
monohydrate and matched placebo doses were rounded
to the nearest 0.1 g. The rationale in providing more of
a relative dosage of β-ALA was an attempt to help
normalize the administration β-ALA to body mass to
doses that are commercially available. Participants were
instructed to take divided doses of the supplements at 4
intervals throughout the day with water and/or food, as
close to 8:00 am, 12:00 pm, 4:00 pm and 8:00 pm as
possible. Participants were given supplements one week
at a time and were asked to return the empty containers to
ensure compliance. They also completed supplementation
logs each week to monitor compliance of supplementation.
Muscle analysis
The muscle samples were obtained using a modified
Bergstrom muscle biopsy technique and were analyzed
for phosphocreatine (PCr) and creatine (Cr) content based
on methods from previous studies [32-34]. Percutaneous
muscle biopsies (50–70 mg) were obtained from the mid-
dle portion of the vastus lateralis muscle of the thigh at
the midpoint between the patella and greater trochanter
of the femur. The biopsy needle was inserted 1–2 cm into
the muscle prior to tissue extraction. Once the biopsy was
taken, adipose tissue was trimmed from the muscle speci-
mens and then the muscle sample was immediately frozen
in liquid nitrogen and stored at −80°C for later analysis. A
total of three muscle samples were obtained, two from
one leg and one from the opposite leg (Day 0, 6, & 27).
The left leg was used for pre and post biopsies with the
right leg being used for the mid biopsy.
Muscle tissue samples were analyzed spectrophotomet-
rically in duplicate to determine PCr and Cr content using
methods developed by Harris and colleagues [20,21,32].
Briefly, approximately 50–70 mg of muscle tissue was cut
and placed in a microfuge tube, and then placed in a
vacuum centrifuge (Savant ISS110 SpeedVac Concentrator,
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18–24 hours. Connective tissue was removed from the
dried samples which were then ground into a powder in a
porcelain plate and placed into pre-weighed microfuge
tubes. Muscle metabolites were extracted in a 0.5 M per-
chloric acid/1 mM EDTA solution on ice for 15 minutes,
while periodically vortexing. Samples were then centri-
fuged at 7,000 rpm for 5 minutes. The supernatant was
transferred into a pre-weighed microfuge tube and neu-
tralized with 2.1 M KHCO3/0.3 M MOPS solution. The
samples were then centrifuged again at 7,000 rpm for 5 mi-
nutes and the supernatant was removed and placed into
microfuge tubes and frozen at −80°C.
Extracts were assayed for PCr in the presence of
50 mM Tris buffer, pH 7.4; 1 mM magnesium chloride,
0.5 mM dithiothreitol, 100 μM glucose, 50 μM NADP+,
350 U/mL glucose-6-phosphate dehydrogenase. The assay
was carried out in 13 × 75 glass screw-top tubes using
10 μL of sample to 1 mL of reagent. The reactant solution
was vortexed and read using a fluorometer (Shimadzu
RFMini 150, Japan) with an excitation wavelength of
360 nm and an emission wavelength of 460 nm. Twenty
five mL of hexokinase solution was added to 1 mL of
reagent and stabilized. For PCr, 20 μL of creatine kinase/
sulfodicholorphenol (CK/SDP) solution was added to the
tubes, which were vortexed and incubated in a dark at
room temperature for 60 minutes when samples were
read again for post-reaction absorbance values.
Extracts were assayed for Cr in the presence of 50 mM
imidazole buffer, pH 7.4; 5 mM magnesium chloride;
20 mM potassium chloride; 25 μM phosphoenolpyruvate;
200 μM ATP; 45 μM NADH; 1250 U/mL lactate dehydro-
genase; 2000 U/mL pyruvate kinase. The assay was carried
out in a standard fluorescence microplate reader using
10 μL of sample to 1 mL of reagent. The reactant solution
was vortexed and read using a fluorometer (Shimadzu
RFMini 150, Japan) with an excitation wavelength of
340 nm and an emission wavelength of 460 nm for base-
line absorbance values. Five μL of CK (25 μ/mg) was
added to 1 mL of the above buffer and stabilized using
1 mL of reagent. After 10 minutes the plate was read again
for post-reaction absorbance values. Test to test reli-
ability of duplicate muscle creatine assays was 0.22 ± 2.4%
(r = 0.90) with a coefficient of variation of 6.8%. Creatine
and PCr were analyzed using a SpectraMax 250 (Molecu-
lar Devices, Sunnyvale, CA). All results were expressed as
mmol/kg dry weight (DW). Total muscle creatine content
was calculated by adding the resulting amounts of PCr
and Cr content together.
Muscle carnosine was analyzed using the HPLC proce-
dures developed by Dunnett and Harris [35]. The muscle
samples were prepared using the same drying methods as
before. Muscle samples were analyzed using an Aquity-
UPLC system (Waters, Milford, MA). Chromatographywas performed using a Thermo Scientific Hypersil ODS
(150 mm× 4.6 mm ID) analytical column protected by a
Hypersil ODS guard column. Solvents were filtered to
0.45 μm. Compounds were eluted using a solvent gradient
at ambient temperature with the following mobile phases:
LINE A: Solvent A:20 mM phosphate buffer [(20 mM
Na2HPO4 (2.84 g/l) + 20 mM NaH2PO4.2H2O (3.12 g/l)],
pH 6.8 – tetrahydrofuran (995:5 v/v); LINE B: Solvent B:
20 mM phosphate buffer, pH 6.8 – methanol - acetonitrile
(500:350:150, v/v); LINE C: 100% methanol; LINE D:
100% water; 2 liters 20 mM Na2HPO4 = 5.68 g; 2 liters
20 mM NaH2PO4.2H2O = 6.24 g.
Statistical analysis
Data were analyzed using SPSS 20.0 software (IBM,
Chicago, IL). Missing data, if any, were replaced using
the last observed value or series mean [36]. One-way
Analysis of Variance (ANOVA) was used to analyze base-
line demographic data. Multivariate Analysis of Variance
(MANOVA) with repeated measures was used to analyze
logically-related variables. The Wilks’ Lambda time and
group × time p-levels were used to assess the overall
MANOVA effects. Univariate tests from the MANOVA
are presented to show individual variable results. In some
instances, quadratic interaction p-levels are reported indi-
cating that non-linear but significant differences were
observed among groups over time. On select variables,
delta values or percent change values were calculated and
analyzed by ANOVA with repeated measures in order to
evaluate the change in values from baseline. Data were
considered statistically significant when the p-value was
less than 0.05 while trends were considered when p-values
ranged between 0.05 and 0.10. Tukey’s least significant
difference (LSD) post hoc analyses were used to determine
where the significance was obtained. Cohen’s d calcula-
tions for effect size were performed to assess magnitude
of effect. Non-significant data that showed moderate to
large effects sizes were also noted as trends for follow-up
with larger sample populations. Data are presented as
means ± standard deviation, except group means were
presented ± standard error of the mean.
Results
A total of 32 apparently healthy, recreationally active fe-
males completed the protocol for the present study. Partici-
pants were 21.5 ± 2.8 years, 60.5 ± 6.1 kg, 40.2 ± 3.8 kg fat
free mass, and 26.7 ± 5.8% body fat. One-way ANOVA ana-
lysis revealed no significant differences (p > 0.05) between
groups at baseline for age, weight, fat free mass, body fat
percentage, muscle carnosine, or muscle phosphagen levels.
Muscle carnosine and phosphagen levels
Table 1 presents muscle carnosine and phosphagen levels
observed in the present study. Muscle samples were
Table 1 Muscle carnosine, creatine, phosphocreatine, and total creatine over 4 weeks
BA BAC CRE PLA Time P value
Carnosine (μmol/g)
Baseline 19.74 ± 8.69 20.81 ± 7.66 20.80 ± 2.81 15.70 ± 4.70 19.27 ± 6.50 T = 0.22
4 Weeks 23.68 ± 1.56 24.23 ± 4.09 21.04 ± 7.00 16.53 ± 4.80 21.37 ± 5.31 G = 0.04
Group 21.71 ± 1.44d 22.52 ± 1.34d 20.92 ± 1.44d 16.12 ± 1.70abc T × G = 0.82
Creatine (mmol/kg DW)
Baseline 47.13 ± 19.88 59.82 ± 37.7 72.96 ± 29.59 59.85 ± 7.79 59.92 ± 27.6 Tq = 0.07
1 Week 50.73 ± 26.83 65.49 ± 15.25 88.55 ± 38.72 68.17 ± 7.74 67.80 ± 24.9 G = 0.14
4 Weeks 42.33 ± 16.24 59.90 ± 9.77 67.72 ± 15.94 57.19 ± 8.07 57.28 ± 14.3 T × G = 0.99
Group 46.73 ± 8.26 61.74 ± 6.24 76.4 ± 8.26 61.74 ± 8.26
Phosphocreatine (mmol/kg DW)
Baseline 22.18 ± 4.28 22.94 ± 18.02 31.69 ± 16.54 21.35 ± 4.44 24.29 ± 13.3 T = 0.10
1 Week 25.91 ± 9.88 32.61 ± 19.62 23.43 ± 4.40 24.08 ± 4.23 27.47 ± 13.0 G = 0.98
4 Weeks 34.75 ± 7.38†b 26.87 ± 7.04a 30.51 ± 6.26 31.43 ± 9.39 30.25 ± 7.49 T × Gq = 0.05
Group 27.61 ± 4.69 27.47 ± 3.54 28.55 ± 4.69 25.62 ± 4.69
Total creatine (mmol/kg DW)
Baseline 63.04 ± 23.30 82.75 ± 37.19 105.11 ± 26.57 80.76 ± 11.18 82.89 ± 29.8 T = 0.76
1 Week 59.47 ± 27.07 94.79 ± 8.30 111.98 ± 37.99 85.53 ± 4.39 89.02 ± 26.8 G = 0.02
4 Weeks 74.28 ± 11.40 82.89 ± 5.32 96.89 ± 14.61 85.91 ± 18.07 84.66 ± 13.4 T × G = 0.79
Group 65.60 ± 7.65bc 86.81 ± 5.78a 104.66 ± 7.65a 84.07 ± 7.65
Repeated measures ANOVA was performed on n = 27 (muscle carnosine) and a repeated measures MANOVA was performed on n = 19 (muscle phosphagen) samples.
Individual group and time data are presented as means ± SD while time and group effects are presented as means ± SEM. MANOVA analysis on muscle creatine and
phosphocreatine levels revealed an overall Wilks’ Lambda time (p = 0.22) and group × time (p = 0.80) effects. Univariate ANOVA p-levels from MANOVA analysis are
presented for each variable. BA signifies beta-alanine only group; BAC represents beta-alanine and creatine combined group; CRE represents the creatine only group;
PLA represents the placebo group; T represents time p-level; G represents group p-level, and T × G represents interaction. qrepresents quadratic p-level. † represents
p < 0.05 difference from baseline. arepresents p < 0.05 difference from BA group. brepresents p < 0.05 difference from BAC group. crepresents p < 0.05 difference from
CRE group. drepresents p < 0.05 difference from PLA group.
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cient sample to analyze 27 samples for carnosine and
19 samples for phosphagen levels. Repeated measures
ANOVA analysis revealed no significant time (p = 0.22)
or time × group (p = 0.82) effects among groups in
muscle carnosine levels while a significant group effect
(p = 0.04) was observed with supplementation. Post hoc
analysis revealed that mean muscle carnosine levels in
the PLA group were significantly lower than all other
groups. One-way ANOVA of percent changes in muscle
carnosine levels suggested that those in the BA and BAC
groups observed the greatest increase in muscle carnosine
levels; however, these apparent differences were not
significantly different among groups (BA 35.3 ± 45; BAC
42.5 ± 99; CRE 0.72 ± 27; PLA 13.9 ± 44%, p = 0.59).
Repeated measures MANOVA analysis on muscle creatine
(Cr), phosphocreatine (PCr), and total creatine (Crtot)
content revealed no overall Wilks’ Lamda time (p = 0.22)
or time by group (0.80) effects among groups. Univariate
repeated measures ANOVA revealed significant quadratic
differences among groups in changes in PCr (pq = 0.05).
However, differences observed could not be attributedto creatine supplementation. Delta analysis revealed
that Crtot levels increased to a greater degree after one
week of loading (BA −3.57 ± 31; BAC 12.04 ± 36; CRE
6.86 ± 26; PLA −3.57 ± 31 mmol/kg DW) but these
changes were not maintained during the maintenance
period (BA 11.2 ± 17; BAC 0.13 ± 36; CRE −8.23 ± 29;
PLA 11.2 ± 17 mmol/kg DW) and no time × group effects
were observed among groups (p = 0.79).
Body composition
Table 2 presents changes in body composition and body
water. A MANOVA was run on body weight and DEXA
determined fat mass, fat free mass, and percent body
fat. An overall Wilks’ Lamda time effect was observed
(p < 0.001) with no significant Wilks’ Lamda time by
group effects (p = 0.57). Repeated measures univariate
ANOVA analysis revealed significant time effects in
changes in body weight (p < 0.01), fat mass (p = 0.05),
fat free mass (p < 0.001), and body fat (p = 0.02). How-
ever, no significant time × group effects were observed.
No significant time (p = 0.79) or time × group (p = 0.36)
effects were observed in percent total body water.
Table 2 Changes in body weight, body composition, and body water
BA
(n = 8)
BAC
(n = 9)
CRE
(n = 8)
PLA
(n =7)
Time P value
Body weight (kg)
Baseline 63.16 ± 7.48 59.18 ± 5.42 61.15 ± 5.68 58.60 ± 5.81 60.54 ± 6.10 T = 0.01
1 Week 63.32 ± 7.30 59.33 ± 5.32 61.38 ± 5.94 59.22 ± 6.07 60.82 ± 6.11 G = 0.50
4 Weeks 63.60 ± 7.28 60.16 ± 5.02 61.26 ± 5.65 59.44 ± 5.88 61.14 ± 5.91† T × G = 0.49
Group 63.36 ± 2.14 59.56 ± 2.02 61.26 ± 2.14 59.09 ± 2.29
Fat mass (kg)
Baseline 16.49 ± 4.93 14.10 ± 3.27 14.30 ± 4.88 14.76 ± 3.94 14.89 ± 4.19 T = 0.05
1 Week 15.52 ± 4.30 13.17 ± 2.57 13.86 ± 4.79 13.84 ± 4.07 14.08 ± 3.88† G = 0.50
4 Weeks 16.59 ± 4.67 12.99 ± 3.01 13.44 ± 3.00 14.02 ± 4.39 14.23 ± 3.88 T × G = 0.57
Group 16.20 ± 1.38 13.42 ± 1.30 13.89 ± 1.38 14.21 ± 1.47
Fat free mass (kg)
Baseline 41.08 ± 4.20 39.77 ± 4.42 41.36 ± 3.33 38.40 ± 3.18 40.19 ± 3.35 T = 0.000
1 Week 42.05 ± 3.78 40.86 ± 4.65 42.06 ± 3.17 39.86 ± 3.38 41.23 ± 3.76† G = 0.59
4 Weeks 41.40 ± 4.35 41.72 ± 4.44 42.55 ± 3.85 39.92 ± 3.09 41.45 ± 3.93† T × G = 0.17
Group 41.51 ± 1.35 40.78 ± 1.27 41.99 ± 1.35 39.40 ± 1.44
Percent fat (%)
Baseline 28.23 ± 6.72 26.03 ± 5.25 25.25 ± 6.62 27.51 ± 5.34 26.71 ± 5.84 T = 0.02
1 Week 26.51 ± 5.08 24.40 ± 4.56 24.34 ± 6.52 25.46 ± 5.23 25.14 ± 5.19† G = 0.62
4 Weeks 28.25 ± 6.34 23.76 ± 5.14 23.88 ± 4.11 25.60 ± 5.94 25.32 ± 5.48† T × G = 0.45
Group 27.66 ± 1.88 24.73 ± 1.78 24.49 ± 1.88 26.19 ± 2.02
Total body water (%)
Baseline 51.31 ± 4.09 53.79 ± 6.56 48.86 ± 5.48 50.90 ± 4.48 51.30 ± 5.33 T = 0.66
1 Week 51.27 ± 3.83 52.56 ± 4.22 50.53 ± 3.61 50.01 ± 3.39 51.15 ± 3.72 G = 0.44
4 Weeks 50.61 ± 3.06 53.33 ± 3.96 51.66 ± 3.66 50.53 ± 3.08 51.59 ± 3.66 T × G = 0.30
Group 51.07 ± 1.45 53.23 ± 1.35 50.35 ± 1.47 50.48 ± 1.45
Individual group and time data are presented as means ± SD while time and group effects are presented as means ± SEM. MANOVA analysis on DEXA body
composition revealed overall Wilks’ Lambda time (p < 0.001) and group × time (p = 0.57) effects. Univariate ANOVA p-levels from MANOVA analysis are presented
for each body composition variable. BA signifies beta-alanine only group; BAC represents beta-alanine and creatine combined group; CRE represents the creatine
only group; PLA represents the placebo group; T represents time p-level; G represents group p-level, and T × G represents interaction. † represents p < 0.05 difference
from baseline.
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Table 3 presents changes observed among groups in
VO2peak, time to exhaustion, metabolic equivalents
(METS), and ventilatory anaerobic threshold (VANT).
MANOVA analysis revealed an overall Wilks’ Lamda
time effect (p = 0.049) and time × group effects (p = 0.017).
Univariate ANOVA analysis revealed significant time
effects in VANT (p < 0.001) with no significant time
effects observed VO2peak (p = 0.54), time to exhaustion
(p = 0.30), and METS (p = 0.35). Interaction trends were
observed among groups in VO2peak (pq = 0.07) and METS
(pq = 0.07) with no significant time × group differences
observed among groups in time to exhaustion (pq = 0.13)
of VANT (p = 0.19). However, post-hoc analysis did
not reveal any meaningful changes over time among or
between groups.Blood lactate and lactate threshold
Blood lactate levels observed during aerobic capacity
testing is presented in Table 4. No significant differences
were observed among groups in pre-exercise lactate levels.
MANOVA analysis revealed no overall Wilks’ Lamda time
(p = 0.33) or group × time (p = 0.34) effects. ANOVA
univariate analysis revealed a significant time × group
interaction (p = 0.05) was observed in peak lactate among
groups. Post-hoc analysis revealed that participants in the
BA group had a significantly higher baseline peak lactate
response than other groups and that peak lactate levels
decreased after 4-weeks of supplementation after BA
supplementation despite performing similar amounts of
work. Participants in the BA group also experienced
significantly less change in resting to maximal lactate
levels despite performing similar amounts of work after
Table 3 Aerobic exercise capacity results observed among groups
BA
(n = 8)
BAC
(n = 8)
CRE
(n = 8)
PLA
(n =6)
Time P value
VO2peak (ml/kg/min)
Baseline 41.50 ± 5.60 40.85 ± 6.98 34.20 ± 5.73 35.88 ± 9.65 38.26 ± 7.33 T = 0.54
1 Week 41.58 ± 5.96 39.89 ± 7.62 36.10 ± 6.04 33.75 ± 10.5 38.10 ± 7.72 G = 0.20
4 Weeks 41.53 ± 6.12 39.35 ± 6.96 35.34 ± 2.98 37.90 ± 9.03 38.57 ± 6.52 T × Gq = 0.07
Group 41.53 ± 2.35 40.03 ± 2.35 35.21 ± 2.35 35.84 ± 2.72
Time to exhaustion (sec)
Baseline 1,249 ± 210 1,185 ± 303 963 ± 289 1,093 ± 324 1,125 ± 290 T = 0.30
1 Week 1,294 ± 246 1,196 ± 360 1,020 ± 251 1,032 ± 314 1,142 ± 303 G = 0.24
4 Weeks 1,293 ± 240 1,173 ± 319 1,046 ± 198 1,083 ± 310 1,153 ± 273 T × Gq = 0.13
Group 1,279 ± 97 1,185 ± 97 1,010 ± 97 1,069 ± 112
METS
Baseline 11.88 ± 1.60 11.63 ± 2.00 9.79 ± 1.64 10.27 ± 2.77 10.93 ± 2.09 T = 0.56
1 Week 11.88 ± 1.70 11.41 ± 2.19 10.31 ± 1.74 9.63 ± 3.00 10.89 ± 2.21 G = 0.20
4 Weeks 11.85 ± 1.74 11.25 ± 1.98 10.09 ± 0.85 10.83 ± 2.54 11.02 ± 1.86 T × Gq = 0.07
Group 11.87 ± 0.67 11.43 ± 0.67 10.06 ± 0.37 10.24 ± 0.78
Ventilatory threshold (%VO2peak)
Baseline 86.81 ± 8.73 86.44 ± 10.73 77.01 ± 6.46 85.75 ± 10.64 83.89 ± 9.68 T < 0.001
1 Week 84.06 ± 7.34 85.35 ± 10.47 78.61 ± 10.53 84.78 ± 11.03 83.30 ± 9.79 G = 0.44
4 Weeks 78.59 ± 9.75 78.26 ± 13.02 76.50 ± 11.21 75.30 ± 9.63 77.29 ± 10.58†ǂ T × G = 0.19
Group 83.15 ± 2.92 83.35 ± 2.92 77.38 ± 2.92 82.29 ± 3.73
Individual group and time data are presented as means ± SD while time and group effects are presented as means ± SEM. MANOVA analysis revealed overall
Wilks’ Lambda time (p < 0.049) and group × time (p = 0.017) effects. Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. BA signifies
beta-alanine only group; BAC represents beta-alanine and creatine combined group; CRE represents the creatine only group; PLA represents the placebo group;
T represents time p-level; G represents group p-level, and T × G represents interaction. q represents quadratic p-level. † represents p < 0.05 difference from
baseline. ǂ represents p < 0.05 difference from 1 week.
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significant differences for lactate threshold between
groups or over time.Anaerobic exercise performance
Results from the Wingate anaerobic capacity testing are
presented in Table 5 and Figure 3. Peak Power (PP)
normalized to body weight demonstrated a significant
time × group ×Wingate interaction (p = 0.02). Relative
mean power, total work, and rate of fatigue significantly
decreased from the first to second Wingate anaerobic
capacity tests. Significant time ×Wingate × group effects
were observed among groups in relative peak power
(p = 0.02) and rate of fatigue (p = 0.04). Post-hoc analysis
demonstrated that placebo relative peak power and rate
of fatigue values were lower than other groups at base-
line no differences among groups after 1 or 4 weeks of
supplementation. Additionally, relative peak power in the
second sprint test in the CRE group was significantly
greater than PLA values after 4 weeks of supplementation.
Rate of fatigue after 4-weeks of supplementation was sig-
nificant higher in the BA group compared to initial fatiguevalues when performing the second Wingate test before
supplementation.
Effect size analysis
Results from effect size calculations (Cohen’s d) are
presented in Table 6. Cohen’s d effect size calculations
were performed to compare supplementation group
means to placebo after four weeks of supplementation
to assess magnitude of effects. In comparison to pla-
cebo responses, BA supplementation resulted in large
effects sizes for muscle carnosine (−2.00), muscle creat-
ine (1.16), and rate of fatigue after the first (−1.44) and
second (−1.25) Wingate test; BAC supplementation
resulted in large effect sizes for muscle carnosine
(−1.73) and rate of fatigue following the first Wingate
test (−0.90); while CRE supplementation resulted in
large effect sizes for changes in muscle creatine (−0.83)
and moderate effect sizes for changes in muscle carno-
sine (−0.75), fat free mass (−0.69), and peak power
during the first Wingate test (−0.83). These findings
indicate that follow-up study with a larger sample size
may reveal additional statistically significant findings
among groups in these variables.
Table 4 Blood lactate results observed during the maximal exercise test
BA
(n = 8)
BAC
(n = 9)
CRE
(n = 8)
PLA
(n =7)
Time P value
Resting lactate (mmol/L)
Baseline 1.44 ± 0.64 1.51 ± 0.44 1.33 ± 0.24 2.03 ± 0.96 1.56 ± 0.63 T = 0.71
1 Week 1.60 ± 0.61 1.43 ± 0.58 1.18 ± 0.28 1.54 ± 0.46 1.43 ± 0.51 G = 0.15
4 Weeks 1.58 ± 0.43 1.36 ± 0.49 1.53 ± 0.47 1.66 ± 0.45 1.52 ± 0.45 T × G = 0.38
Group 1.54 ± 0.12 1.43 ± 0.11 1.34 ± 0.12 1.74 ± 0.13
Peak lactate (mmol/L)
Baseline 12.91 ± 4.48bcd 8.63 ± 3.34a 9.71 ± 1.83a 7.54 ± 2.26 9.73 ± 3.64 T = 0.10
1 Week 10.43 ± 2.27 8.93 ± 3.18 9.20 ± 2.15 8.76 ± 1.25 9.33 ± 2.36 G = 0.07
4 Weeks 9.85 ± 1.89† 8.04 ± 2.59 8.99 ± 1.46 8.64 ± 2.28 8.87 ± 2.12 T × G = 0.05
Group 11.06 ± 0.77bd 8.54 ± 0.73a 9.30 ± 0.77 8.31 ± 0.83a
Lactate threshold (% Peak VO2)
Baseline 65.18 ± 8.37 67.12 ± 14.08 66.09 ± 7.54 66.40 ± 10.14 66.22 ± 7.45 T = 0.14
1 Week 68.86 ± 5.98 69.92 ± 7.44 67.31 ± 6.64 64.51 ± 6.88 67.82 ± 6/75 G = 0.91
4 Weeks 67.04 ± 7.66 69.04 ± 6.91 69.61 ± 9.42 73.53 ± 5.83 69.67 ± 7.58 T × G = 0.86
Group 67.03 ± 1.73 68.70 ± 1.63 67.67 ± 1.73 68.15 ± 1.85
Onset of blood lactate (%VO2peak)
Baseline 77.50 ± 9.89 82.94 ± 10.9 81.71 ± 8.82 83.81 ± 8.82 81.47 ± 9.54 T = 0.13
1 Week 78.50 ± 10.1 84.90 ± 9.30 83.48 ± 7.67 75.17 ± 17.43 80.82 ± 11.5 G = 0.58
4 Weeks 84.14 ± 8.35 86.68 ± 8.51 83.76 ± 11.68 84.77 ± 11.93 84.90 ± 9.70 T × G = 0.81
Group 80.05 ± 2.61 84.84 ± 2.46 82.98 ± 2.61 81.25 ± 2.79
Blood lactate difference from baseline to max (mmol/L)
Baseline 11.48 ± 4.19bcd 7.10 ± 3.52a 8.39 ± 1.75ad 5.51 ± 2.15ac 8.17 ± 3.67 T = 0.08
1 Week 8.83 ± 2.64† 7.43 ± 3.31 8.03 ± 2.03 7.20 ± 1.59 7.88 ± 2.49 G = 0.06
4 Weeks 8.28 ± 1.88† 6.61 ± 2.73 7.46 ± 1.26 6.81 ± 2.24 7.28 ± 2.12 T × G = 0.02
Group 9.53 ± 0.79 7.05 ± 0.74 7.96 ± 0.79 6.51 ± 0.84
Individual group and time data are presented as means ± SD while time and group effects are presented as means ± SEM. MANOVA analysis revealed overall
Wilks’ Lambda time (p = 0.33) and group × time (p = 0.34) effects. Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. BA signifies
beta-alanine only group; BAC represents beta-alanine and creatine combined group; CRE represents the creatine only group; PLA represents the placebo group; T
represents time p-level; G represents group p-level, and T × G represents interaction. † represents p < 0.05 difference from baseline. arepresents p < 0.05 difference
from BA group. brepresents p < 0.05 difference from BAC group. crepresents p < 0.05 difference from CRE group. drepresents p < 0.05 difference from PLA group.
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The present study sought to determine whether co-
supplementation of creatine monohydrate and β-ALA
would provide additive ergogenic benefits on body com-
position, aerobic and/or anaerobic exercise performance
in recreationally-active females. We hypothesized that
co-supplementation of β-ALA and creatine monohydrate
may lead to greater ergogenic and performance adapta-
tions by synergistically enhancing anaerobic threshold,
aerobic capacity, time to exhaustion, and/or the ability to
perform repeated 30-second sprints. Results revealed that
although some benefits were found from β-ALA and cre-
atine supplementation, there appeared to be little additive
benefits from co-supplementation in recreationally active
women. The following provides additional assessment of
results observed.Muscle carnosine and phosphagens
Harris and colleagues [3] reported that β-ALA supple-
mentation (3.2 g/day) resulted in a 42% increase in muscle
carnosine levels after four weeks of supplementation.
Results in the present study showed a mean increase in
muscle carnosine levels of 35.3 ± 45% following BA
supplementation and 42.5 ± 99% following BAC supple-
mentation with average doses of 6.1 ± 0.7 g/day of β-ALA.
While these mean changes in muscle carnosine levels
following β-ALA supplementation are consistent with
values reported in other studies [3,10,37-40] and we found
some group effects with large effect sizes, no statistically
significant interactions were observed among groups in
muscle carnosine levels. The lack of statistical significance
was apparently due to the large variability in muscle carno-
sine levels observed in response to β-ALA supplementation,
Table 5 Anaerobic capacity repeated sprint performance results
BA
(n = 8)
BAC
(n = 9)
CRE
(n = 8)
PLA
(n =7)
Time P value
Peak power (W/kg)
Wingate 1
Baseline 15.24 ± 4.87d 14.74 ± 5.81d 15.00 ± 3.95d 11.09 ± 2.33abc 14.13 ± 4.62 T = 0.67
1 Week 15.68 ± 3.85 13.88 ± 2.95 14.63 ± 2.82 13.43 ± 1.93 14.42 ± 2.97 G = 0.46
4 Weeks 14.77 ± 1.82 13.00 ± 3.40 13.46 ± 2.69 14.26 ± 4.73† 13.83 ± 3.19 T × G = 0.58
Wingate 2 G ×W= 0.91
Baseline 13.51 ± 1.37 13.22 ± 3.15 12.70 ± 3.22† 13.77 ± 3.62 13.28 ± 2.83 W = 0.59
1 Week 14.97 ± 1.95 14.96 ± 3.80 13.30 ± 3.38 12.67 ± 3.04 14.05 ± 3.16 T ×W = 0.46
4 Weeks 13.68 ± 1.40 13.60 ± 3.89 15.48 ± 4.47 12.61 ± 2.47 13.87 ± 3.33 T ×W × G = 0.02
Mean power (W/kg)
Wingate 1
Baseline 6.13 ± 0.97 5.77 ± 0.59 5.87 ± 0.53 5.44 ± 1.21 5.81 ± 0.84 T = 0.46
1 Week 6.25 ± 0.83 5.89 ± 0.65 6.01 ± 0.65 5.39 ± 0.67 5.90 ± 0.74 G = 0.36
4 Weeks 6.07 ± 0.80 5.75 ± 0.61 5.65 ± 0.86 5.69 ± 0.76 5.79 ± 0.74 T × G = 0.48
Wingate 2 G ×W= 0.89
Baseline 5.60 ± 0.87 5.42 ± 0.55 5.20 ± 0.54 5.10 ± 1.01 5.34 ± 0.74 W = 0.006
1 Week 5.48 ± 0.86 5.48 ± 0.62 5.37 ± 0.64 5.21 ± 0.96 5.39 ± 0.74 T ×W =0.58
4 Weeks 5.27 ± 0.86 5.34 ± 0.57 5.19 ± 0.71 5.14 ± 1.05 5.24 ± 0.76 T ×W × G = 0.70
Total work (J)
Wingate 1
Baseline 11,467 ± 1,048 10,476 ± 1,499 10,764 ± 1,420 9,541 ± 2,262 10,591 ± 1,653 T = 0.97
1 Week 11,793 ± 1,438 10,719 ± 1,531 11,081 ± 1,726 9,566 ± 1,422 10,826 ± 1,660 G = 0.07
4 Weeks 11,494 ± 1,430 10,561 ± 1,223 10,437 ± 2,071 10,152 ± 1,698 10,674 ± 1,621 T × G = 0.33
Wingate 2 G ×W= 0.92
Baseline 10,565 ± 1,862 9,878 ± 1,678 9,545 ± 1,235 8,939 ± 1,800 9,761 ± 1,678 W = 0.02
1 Week 10,363 ± 1,767 9,986 ± 1,617 9,903 ± 1,605 8,220 ± 1,673 9,892 ± 1,633 T ×W =0.48
4 Weeks 10,019 ± 1,785 9,835 ± 1,320 9,548 ± 1,556 9,168 ± 2,041 9,663 ± 1,619 T ×W × G = 0.66
Rate of fatigue (%)
Wingate 1
Baseline 107.4 ± 13.9d 104.1 ± 14.3d 103.7 ± 21.0 92.4 ± 9.4ab 102.3 ± 15.6 T = 0.40
1 Week 105.8 ± 14.1 102.0 ± 9.9 96.2 ± 16.6 108.4 ± 9.4† 102.9 ± 13.1 G = 0.09
4 Weeks 109.8 ± 10.9d 103.4 ± 10.3 104.2 ± 15.9 93.1 ± 12.4a 102.7 ± 13.1 T × G = 0.52
Wingate 2 G ×W= 0.96
Baseline 91.7 ± 12.0† 101.9 ± 11.4 96.0 ± 14.8 92.9 ± 13.7 95.9 ± 13.0 W = 0.02
1 Week 102.4 ± 9.5 97.9 ± 13.5 99.6 ± 11.2 90.3 ± 21.0 97.8 ± 14.1 T ×W = 0.66
4 Weeks 108.5 ± 13.8‡bd 95.3 ± 16.6ad 99.6 ± 15.9d 82.8 ± 11.1abc 99.1 ± 15.2 T ×W × Gq = 0.04
Data are means ± SD. BA signifies beta-alanine only group; BAC represents beta-alanine and creatine combined group; CRE represents the creatine only group;
PLA represents the placebo group; T represents time p-level; G represents group p-level, W represents Wingate p-level, T × G represents time by group interaction,
T ×W × G represents time × group ×Wingate interactions, q represents quadratic p-level. MANOVA analysis revealed overall Wilks’ Lambda time (p = 0.004), T × G
(0.65), T ×W (0.97), and T × G ×W effects (p = 0.21). Univariate ANOVA p-levels from MANOVA analysis are presented for each variable. † represents p < 0.05 difference
from Wingate 1 baseline while ‡ represents p < 0.05 difference from Wingate 2 baseline. arepresents p < 0.05 difference from BA group. brepresents p < 0.05 difference
from BAC group. crepresents p < 0.05 difference from CRE group. drepresents p < 0.05 difference from PLA group. B
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Figure 3 Wingate anaerobic capacity peak power and rate of
fatigue results. Data are means ± SD. BA signifies beta-alanine only
group; BAC represents beta-alanine and creatine combined group;
CRE represents the creatine only group; and, PLA represents the
placebo group. * represents p < 0.05 difference between PLA and
BA, BAC, or CRE groups. † represents p < 0.05 difference from
Wingate 1 baseline while ‡ represents p < 0.05 difference from
Wingate 2 baseline.
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research is needed to determine the effects of β-ALA sup-
plementation on muscle carnosine levels in recreationally-
active women.
In terms of muscle phosphagen changes, it is import-
ant to note that the sample size for muscle creatine and
phosphagen assessment was quite small due to prioritiz-
ing muscle carnosine assays as well as some samples not
being large enough to run the appropriate assays. There-
fore, statistical power is relatively low on these data. The
creatine dosages used in the present study (0.3 g/kg/day
of creatine for week 1 and 0.1 g/kg/day for weeks 2–4)
are similar to those used with previous studies that
indicate significant increases in muscle creatine after a
loading and maintenance phase [19,21]. Results from
the present study found non-significant increases in
muscle creatine (+21%, +9.4%) and total creatine con-
tent (+6.5%, +14.5%) following creatine and β-ALA pluscreatine supplementation after 1-week of loading and
3-weeks of maintenance doses, respectively. While overall
results were not statistically significant, mean changes
observed support previous studies that have reported that
creatine loading (e.g., 20 g/day or 0.3 g/kg/d for 5 to
7-days) results in an increase in muscle creatine content
by 10–40% [16,19-21,31,41] and a large effect size was
observed following creatine supplementation. While the
lack of significance may have simply been a result of
the small sample size, it is also known that there is
individual variability in response to creatine supplementa-
tion [19-21]. Additionally, measurement of muscle PCr
levels can be challenging.
It is also possible that sex may have played a role in
response to creatine and/or β-ALA supplementation. In
this regard, most studies on creatine and β-ALA supple-
mentation have been conducted on males and there is
some evidence that females may respond differently to
creatine and/or β-ALA supplementation. For example,
Fosberg and colleagues [42] reported that females had
greater total creatine amounts relative to tissue weight;
however, other studies show there is no difference between
males and females [40,43]. There are also some data sug-
gesting that men may have greater muscle carnosine levels
than women [4,44]; however, a recent study showed sex did
not have an effect on increasing carnosine levels with
supplementation [40]. Additionally, Bex and coworkers [45]
reported that carnosine loading is more pronounced in
trained versus untrained individuals. Thus, it is possible
that sex and/or the types and/or amounts of training per-
formed among participants may have influenced response
to creatine and/or β-ALA supplementation.
Body composition
As expected, body weight and markers of body compos-
ition improved over time during training in all groups.
However, no significant differences were observed among
groups. These findings support findings that females may
experience less changes in body mass and/or fat free mass
in response to creatine supplementation during training
than is typically observed in men [16]. Present findings
also support Kendrick et al. [39] who found that 10-weeks
of β-ALA supplementation (6.4 g/day) had no effects on
body composition. However, Hoffman and associates [22]
reported that supplementation of β-ALA with creatine
promoted greater gains in lean body mass compared to
creatine alone in male strength/power athletes. Smith and
colleagues [12] reported that beta alanine supplementation
during high-intensity interval training in men promoted
improvements in exercise capacity and lean body mass.
Additionally, Kern and Robinson [46] reported that β-
ALA supplementation (4 g/day for 8 weeks) in college
wrestlers and football players augmented performance
and increased lean mass accrual. The reason for the
Table 6 Effect size calculations
BA BAC CRE
Carnosine −2.00 (large) −1.73 (large) −0.75 (moderate)
Creatine 1.16 (large) −0.30 (low) −0.83 (large)
Phosphocreatine −0.39 (low) 0.55 (low) 0.12 (low)
Total Creatine 0.77 (moderate) −0.22 (low) 0.08 (low)
Body Weight −0.63 (moderate) −0.29 (low) −0.33 (low)
Fat Mass −0.37 (low) 0.02 (low) 0.15 (low)
Fat Free Mass −0.36 (low) −0.46 (low) −0.69 (moderate)
Percent Body Fat −0.43 (low) 0.12 (low) 0.34 (low)
VO2peak −0.47 (low) −0.02 (low) 0.38 (low)
Max Time −0.76 (moderate) −0.16 (low) 0.14 (low
Ventilatory Threshold −0.34 (low −0.4 (low) −0.11 (low)
Peak Lactate −0.58 (moderate) 0.38 (low) −0.18 (low)
Lactate Threshold −0.05 (low) −0.12 (low) −0.28 (low
Peak Power Wingate 1 −0.36 (low) 0.21 (low) 0.11 (low)
Peak Power Wingate 2 −0.80 (moderate) −0.39 (low) −0.83 (moderate)
Total Work Wingate 1 −0.85 (large) −0.28 (low) 0.15 (low)
Total Work Wingate 2 −0.44 (low) −0.39 (low) −0.21 (low)
Rate of Fatigue Wingate 1 −1.44 (large) −0.90 (large) −0.78 (low)
Rate of Fatigue Wingate 2 −1.25 (large −0.17 (low) −0.49 (low
Cohen’s d calculations compared each group mean to PLA.
All calculations used data from week 4.
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the present study remain unclear but may be due to differ-
ences in sex and/or training programs among participants.Aerobic exercise performance
Creatine supplementation has been purported to provide a
mild effect on aerobic exercise capacity possibly through an
increase in anaerobic threshold although the literature is
mixed on this relationship [16]. Baguet et al. [9], used a
similar supplementation protocol for β-ALA as the present
study with physically active males and found no effects
on VO2peak as a result of supplementation. Stout and
colleagues [13] measured the effects of β-ALA supple-
mentation on VT in females. They supplemented for
28 days and found that VT and time to exhaustion were
increased in the β-ALA group. The present study was
unable to show similar results with β-ALA supplementa-
tion groups. There was a slight trend with the creatine
only group towards improvement in time to VO2peak, but
this was not statistically significant. The lack of signifi-
cance in the present study could be due to differences in
training programs among participants and/or low power
and effect size of the data. It is unlikely that familiarity
was a major factor as all participants underwent famil-
iarization tests on the cycle ergometer prior to starting the
study protocol.Blood lactate and lactate threshold
The increase in muscle carnosine following supplemen-
tation would theoretically reduce blood lactate levels
during submaximal exercise and/or increase LT since one
of the main functions of carnosine is as an intramuscular
pH buffer. Although the carnosine results between groups
in the present study were not significant, the groups sup-
plemented with β-ALA showed greater percent changes
compared to those without. The percent increase also
compares closely to previous studies with significant
results [3], therefore some inferences can be made based
on this trend. The present study found a significant differ-
ence in peak lactate achieved during the maximal aerobic
capacity test for the group supplementing with β-ALA
over the combined supplementation and placebo. How-
ever, the study failed to show any differences with LT
between the groups, only a trend of β-ALA supplementa-
tion improving levels after one week. Previous studies
have reported mixed results pertaining to the effect of
β-ALA and creatine supplementation on blood lactate
accumulation and LT. Van Thienen and colleagues [47]
reported no difference between groups in blood lactate
levels in healthy males after an incremental maximal
cycle ergometer test followed by a 30 second all out sprint
after eight weeks of supplementation with β-ALA (2–3 g/d
weeks 1–4 and 4 g/d for weeks 4–8) or placebo. Zoeller
et al. [15] studied 55 men who supplemented with β-ALA
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for 28 days and reported a greater VO2peak at LT for the
combined supplementation group, suggesting that this
supplementation protocol may delay the onset of LT
during incremental exercise.
The present study may have failed to show improve-
ments in lactate accumulation and LT with β-ALA alone
or the combined β-ALA and creatine supplementation
strategy for various reasons. First, the power analysis
and effect size calculations were low, which indicates the
strength of the data could be improved, possibly with a
larger sample size. Also, the present study examined the
effects of supplementation in recreationally active females,
who did not engage in a standardized training program
during the four weeks of the study. Perhaps with a training
program, like one seen in other studies, there may have
been training effects seen for lactate variables. Finally,
since we did not observe statistically significant differences
in muscle carnosine or phosphagen levels due to large
variation in response to the supplementation protocol,
variability in measurement, and/or low statistical power; it
is possible that this may have limited the potential ergo-
genic benefit.
Anaerobic exercise performance
Creatine supplementation has been consistently reported
to increase anaerobic sprint and/or exercise capacity [16].
For example, Kreider and colleagues [48] reported that
creatine supplementation (15 g/day for 28-days) signifi-
cantly increased repetitive sprint performance and muscle
mass during training in college football players. Wiroth
and colleagues [49] reported that creatine supplementa-
tion improved maximal power and work during a set of
5 × 10 second sprints on the cycle ergometer. Green and
colleagues [50] reported that creatine supplementation
(20 g/day for 6-days) increased PP during the first arm
Wingate test and the decline in performance was less after
the second leg Wingate test. Ziegenfuss et al. [51] also
showed that creatine supplementation in college athletes
resulted in increased TW and PP during multiple maximal
10-sec sprints on a cycle ergometer. Results from the
present study, however, did not reveal an ergogenic benefit
when performing repeated 30-sec anaerobic capacity tests.
These findings may be related to the length of the sprint
which is generally more dependent on glycolytic capacity
rather than phosphagen availability.
A number of studies have also reported that β-ALA
supplementation provides ergogenic benefit during high
intensity exercise [1,2,5,44,47]. For example, Hill and
colleagues [10] reported that 10-weeks of β-ALA supple-
mentation significantly increased total work performed
during high-intensity cycling by approximately 13%. Van
Thienen et al. [47] reported that β-ALA supplementa-
tion (2.4 g/day for 8-weeks) significantly increased sprintperformance at the end of an exhausted endurance
cycling exercise bout. Hoffman et al. [52] reported that
β-ALA supplementation (4.5 g/day for 3-weeks) in college
football players tended to decrease fatigue rate during
sprint exercise (p = 0.07). Another study by this group [22]
examined the effects of creatine alone, β-ALA and creat-
ine combined and placebo supplementation for 10-weeks
in strength power athletes. The researchers reported
some beneficial effects on improvements in strength
and lean tissue accretion from β-ALA and/or creatine
supplementation. Tobias et al. [53] reported that β-ALA
supplementation (6.4 g/day for 4-weeks) significantly
improved repetitive anaerobic capacity while performing
4 × 30-sec sprints in judo and jujitsu athletes. Similarly,
De Salles Painelli and coworkers [54] reported that β-ALA
supplementation (6.4 g/day for 4-weeks) significantly im-
proved anaerobic capacity while performing 4 × 30-sec
sprints in untrained and trained men. In the present study,
there was some evidence that β-ALA supplementation
may have led to an improvement in rate of fatigue after
four weeks of supplementation. However, we did not
find that β-ALA with creatine supplementation improved
repetitive bouts of 30-sec sprint performance in recre-
ationally active women. It is possible that greater benefits
may have been observed from performing more than two
30-sec Wingate sprints as noted above and/or longer
sprints. In this regard, Hobson et al. [11] reported that β-
ALA supplementation was effective in improving sprint
performance in tasks lasting longer than 60-seconds.
Saunders et al. [55] tested this theory in a study utilizing
the YoYo Intermittent Recovery Test in participants sup-
plementing with β-ALA for 12 weeks. This test is designed
to assess the ability to perform and recover from multiple
sprints, as seen in many sports. They found supplementa-
tion improved performance on this test and suggested
it was due to enhanced muscle buffering capabilities
between bouts of high intensity exercise resulting from
the increased muscle carnosine due to supplementation
with β-ALA [55]. However, more research is needed to
examine the potential ergogenic value of β-ALA with
and without creatine monohydrate supplementation in
this population.
Conclusion
This is one of the first studies to use a more individualized
dosing strategy for β-ALA supplementation instead of
providing a standardized amount β-ALA for all partici-
pants irrespective of difference in body mass. Although
the mean increases in muscle carnosine levels were similar
to those reported in the literature, changes in muscle car-
nosine levels were not statistically increased in the present
study. The lack of significance may have been due to the
dosing strategy employed in that the calculated doses may
not have been great enough to elicit positive responses.
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ing a different amount of β-ALA to consistently increase
muscle carnosine levels compared to males. Further, the
small sample size of the present study resulting in low
power and effect sizes in some instances may have
contributed to the lack of significant findings as previous
research has demonstrated that four weeks of creatine and
β-ALA supplementation was sufficient to increase muscle
carnosine and phosphagen levels. Moreover, results of the
present study did not show supplementation to have sig-
nificant effects on body composition, aerobic or anaerobic
performance measures. However, perhaps a greater total
amount of β-ALA is needed to be ingested over time in
women in order for performance adaptations to occur,
especially without the addition of a standardized exercise
training program. Further studies should be conducted to
examine the potential independent and synergistic effects
of a combined supplementation of creatine, β-ALA, and
other purported nutritional ergogenic aids in untrained
and trained male and female populations. Additionally,
future studies should examine the effects of combined
supplementation on muscle carnosine and phosphagen
levels in a larger and/or more active population.
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